Brief: Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154
26/03/2025 12:01
March 26 (Reuters) - Lipocine Inc LPCN.O: LIPOCINE ANNOUNCES INITIATION OF OUTPATIENT PHASE 3 POSTPARTUM DEPRESSION TRIAL OF LPCN 1154 LIPOCINE INC: PATIENT DOSING EXPECTED IN Q2/2025 Source text: ID:nPnyMjw5a Further company coverage: LPCN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lipocine
See all newsUS STOCKS ON THE MOVE-Halozyme, Moderna, Merck
U.S. STOCKS ON THE MOVE-Halozyme, BKV, AppFolio
U.S. STOCKS ON THE MOVE-Hecla Mining, XPO, Lipocine
Lipocine surges after Canada approves co's testosterone replacement therapy
Brief: Lipocine Announces Health Canada Approval Of Tlando For Testosterone Replacement Therapy